Jennison Associates LLC acquired a new stake in shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 480,828 shares of the company’s stock, valued at approximately $2,899,000. Jennison Associates LLC owned about 2.02% of Longboard Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Bourgeon Capital Management LLC acquired a new position in shares of Longboard Pharmaceuticals in the third quarter valued at approximately $39,000. TD Asset Management Inc increased its stake in Longboard Pharmaceuticals by 149.8% in the 3rd quarter. TD Asset Management Inc now owns 121,422 shares of the company’s stock valued at $675,000 after buying an additional 72,811 shares during the period. Finally, Polar Capital Holdings Plc purchased a new position in Longboard Pharmaceuticals during the 3rd quarter worth $5,560,000. 63.28% of the stock is owned by hedge funds and other institutional investors.
Longboard Pharmaceuticals Trading Up 2.4 %
Longboard Pharmaceuticals stock opened at $19.72 on Friday. The firm’s 50-day simple moving average is $20.04 and its 200 day simple moving average is $14.40. Longboard Pharmaceuticals, Inc. has a 52 week low of $3.60 and a 52 week high of $28.15.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on LBPH. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $60.00 target price on shares of Longboard Pharmaceuticals in a report on Wednesday, April 10th. Wedbush reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Longboard Pharmaceuticals in a report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Longboard Pharmaceuticals in a research note on Tuesday, April 16th. Citigroup initiated coverage on Longboard Pharmaceuticals in a report on Friday, February 16th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Guggenheim upped their price objective on Longboard Pharmaceuticals from $16.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Longboard Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $44.80.
View Our Latest Report on LBPH
Longboard Pharmaceuticals Company Profile
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
See Also
- Five stocks we like better than Longboard Pharmaceuticals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks Leading the U.S. Agriculture Comeback
- Most Volatile Stocks, What Investors Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is Forex and How Does it Work?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding LBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report).
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.